Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (177) 177
newly-diagnosed glioblastoma (156) 156
index medicus (153) 153
oncology (129) 129
glioblastoma (91) 91
gliomas (81) 81
chemotherapy (80) 80
clinical neurology (73) 73
phase-ii trial (71) 71
temozolomide (69) 69
glioma (68) 68
brain neoplasms - drug therapy (65) 65
radiotherapy (58) 58
glioma - drug therapy (56) 56
male (56) 56
radiation-therapy (56) 56
brain neoplasms - pathology (55) 55
cancer (55) 55
female (54) 54
adult (53) 53
brain tumors (53) 53
brain neoplasms - therapy (50) 50
middle aged (50) 50
adjuvant temozolomide (49) 49
aged (48) 48
prognosis (48) 48
brain neoplasms - genetics (43) 43
medicine & public health (43) 43
care and treatment (42) 42
glioblastoma multiforme (39) 39
glioma - pathology (38) 38
malignant glioma (38) 38
high-grade glioma (36) 36
dacarbazine - analogs & derivatives (35) 35
neurology (35) 35
research (35) 35
survival (35) 35
glioma - therapy (34) 34
treatment outcome (34) 34
recurrent glioblastoma (32) 32
central-nervous-system (31) 31
combined modality therapy (30) 30
phase-iii trial (30) 30
dacarbazine - therapeutic use (29) 29
glioma - genetics (29) 29
animals (28) 28
brain cancer (28) 28
brain neoplasms - radiotherapy (28) 28
growth-factor receptor (28) 28
tumors (28) 28
antineoplastic agents - therapeutic use (27) 27
high-grade gliomas (27) 27
antineoplastic agents, alkylating - therapeutic use (26) 26
bevacizumab (26) 26
neurosciences (26) 26
surgery (26) 26
health aspects (25) 25
mgmt (25) 25
glioblastoma - drug therapy (23) 23
glioblastoma - pathology (23) 23
brain neoplasms - mortality (22) 22
diagnosed glioblastoma-multiforme (22) 22
malignant gliomas (22) 22
pharmacology & pharmacy (22) 22
brain neoplasms - diagnosis (21) 21
drug therapy (21) 21
phase-ii (21) 21
review (21) 21
young adult (21) 21
brain neoplasms - metabolism (20) 20
oligodendroglioma (20) 20
low-grade glioma (19) 19
methylation (19) 19
neoplasm grading (19) 19
radiation therapy (19) 19
glioma - radiotherapy (18) 18
low-grade gliomas (18) 18
multiforme (18) 18
neoplasms (18) 18
retrospective studies (18) 18
development and progression (17) 17
integrated genomic analysis (17) 17
mgmt promoter methylation (17) 17
aged, 80 and over (16) 16
analysis (16) 16
bevacizumab plus irinotecan (16) 16
clinical trials as topic (16) 16
diagnosed anaplastic oligodendrogliomas (16) 16
neurosurgery (16) 16
progression-free survival (16) 16
quality-of-life (16) 16
randomized-trial (16) 16
survival analysis (16) 16
survival rate (16) 16
anaplastic astrocytoma (15) 15
anaplastic oligodendroglioma (15) 15
brain-tumors (15) 15
clinical trials (15) 15
glioblastoma - therapy (15) 15
hematology, oncology and palliative medicine (15) 15
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Treating anaplastic oligodendrogliomas and who grade 2 gliomas: PCV or temozolomide? The case for temozolomide
by Rinne, Mikael L and Wen, Patrick Y
ONCOLOGY (United States), ISSN 0890-9091, 2015, Volume 29, Issue 4, pp. 265 - 275
BRAIN-TUMOR | ONCOLOGY | BEVACIZUMAB | NEWLY-DIAGNOSED GLIOBLASTOMA | LOMUSTINE | VINCRISTINE | RANDOMIZED-TRIAL | PROCARBAZINE | Procarbazine - administration & dosage | Dacarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Dacarbazine - therapeutic use | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Neoplasm Grading | Glioma - pathology | Dacarbazine - analogs & derivatives | Vincristine - administration & dosage | Chemotherapy, Adjuvant | Radiotherapy, Adjuvant | Oligodendroglioma - drug therapy | Oligodendroglioma - mortality | Treatment Outcome | Evidence-Based Medicine | Randomized Controlled Trials as Topic | Antineoplastic Agents, Alkylating - therapeutic use | Oligodendroglioma - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Antineoplastic Agents, Alkylating - adverse effects | Neoplasm Staging | Lomustine - administration & dosage | Glioma - drug therapy
Journal Article
Details down arrow
2. Full Text Synergistic Antitumor Effect between Gefitinib and Fractionated Irradiation in Anaplastic Oligodendrogliomas Cannot Be Predicted by the Egfr Signaling Activity
by Pinel, Sophie and Mriouah, Jihane and Vandamme, Marc and Chateau, Alicia and Plénat, François and Guérin, Eric and Taillandier, Luc and Bernier-Chastagner, Valérie and Merlin, Jean-Louis and Chastagner, Pascal
PLoS ONE, ISSN 1932-6203, 07/2013, Volume 8, Issue 7, p. e68333
In high-grade gliomas, the identification of patients that could benefit from EGFR inhibitors remains a challenge, hindering the use of these agents. Using... 
PHASE-II TRIAL | KINASE INHIBITION | DIAGNOSED GLIOBLASTOMA-MULTIFORME | MULTIDISCIPLINARY SCIENCES | EPIDERMAL-GROWTH-FACTOR | RECURRENT GLIOBLASTOMA | MALIGNANT GLIOMAS | FACTOR RECEPTOR INHIBITION | BRAIN-STEM GLIOMAS | ONCOGENE ADDICTION | RADIATION-THERAPY | Immunohistochemistry | Immunoassay | Chemoradiotherapy - methods | Humans | Treatment Outcome | Phosphoproteins - metabolism | Xenograft Model Antitumor Assays - methods | Oligodendroglioma - radiotherapy | Receptor, Epidermal Growth Factor - metabolism | Animals | Quinazolines - therapeutic use | Statistics, Nonparametric | Dose Fractionation | Female | Signal Transduction - physiology | Combined Modality Therapy - methods | Mice | Quinazolines - pharmacology | Oligodendroglioma - drug therapy | Ionizing radiation | Radiotherapy | Gefitinib | Gliomas | Phosphoproteins | Analysis | Slopes | Animal models | Brain tumors | Brain cancer | Science | AKT protein | Kinases | Cancer therapies | Experiments | Anticancer properties | Proteins | Angiogenesis | Signal transduction | Pathways | Quality | Xenografts | Epidermal growth factor receptors | Abnormalities | Regrowth | Radiation therapy | Addictions | Signaling | Chemotherapy | Glioma | Medical prognosis | Irradiation | Antitumor activity | Combined treatment | PTEN protein | Tumors | Life Sciences | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Oligodendroglioma
by Van den Bent, Martin J and Reni, Michele and Gatta, Gemma and Vecht, Charles
Critical Reviews in Oncology and Hematology, ISSN 1040-8428, 2007, Volume 66, Issue 3, pp. 262 - 272
Abstract Oligodendrogliomas (OD) are rare, diffusely infiltrating tumors, arising in the white matter of cerebral hemispheres, and displaying better... 
Hematology, Oncology and Palliative Medicine | PHASE-III TRIAL | RECURRENT OLIGODENDROGLIOMA | PROGNOSTIC-FACTORS | ONCOLOGY | LOW-GRADE GLIOMA | DIAGNOSED ANAPLASTIC OLIGODENDROGLIOMAS | PCV CHEMOTHERAPY | RANDOMIZED-TRIAL | EUROPEAN-ORGANIZATION | COMPARATIVE GENOMIC HYBRIDIZATION | HEMATOLOGY | RADIATION-THERAPY | Prognosis | Brain Neoplasms - diagnosis | Humans | Oligodendroglioma - diagnosis | Brain Neoplasms - pathology | Oligodendroglioma - complications | Brain Neoplasms - complications | Survival | Incidence | Oligodendroglioma - therapy | Oligodendroglioma - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Brain Neoplasms - therapy | Neoplasm Staging | Radiotherapy, Adjuvant
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Diffuse infiltrating oligodendroglioma and astrocytoma
by Van Den Bent, Martin J and Smits, Marion and Kros, Johan M and Chang, Susan M
Journal of Clinical Oncology, ISSN 0732-183X, 07/2017, Volume 35, Issue 21, pp. 2394 - 2401
The new 2016 WHO brain tumor classification defines different diffuse gliomas primarily according to the presence or absence of IDH mutations (IDH-mt) and... 
BRAIN-TUMOR GROUP | PHASE-III TRIAL | MOLECULAR CLASSIFICATION | GROSS-TOTAL RESECTION | ONCOLOGY | LOW-GRADE GLIOMA | DIAGNOSED ANAPLASTIC OLIGODENDROGLIOMA | TERM-FOLLOW-UP | RANDOMIZED-TRIAL | QUALITY-OF-LIFE | EUROPEAN-ORGANIZATION | Astrocytoma - genetics | Prognosis | Astrocytoma - therapy | Oligodendroglioma - genetics | Humans | Brain Neoplasms - pathology | Brain Neoplasms - genetics | Combined Modality Therapy | Astrocytoma - pathology | Oligodendroglioma - therapy | Neoplasm Grading | Oligodendroglioma - pathology | Brain Neoplasms - therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Oligodendrogliomas: Molecular Biology and Treatment
by Bromberg, Jacolien E. C and van den Bent, Martin J
The Oncologist, ISSN 1083-7159, 02/2009, Volume 14, Issue 2, pp. 155 - 163
Learning Objectives Evaluate the current challenges in the histological diagnosis of oligodendroglial tumors and apply best practices to optimize patient... 
19q | Oligoastrocytoma | Temozolomide | MGMT | Oligodendroglioma | EUROPEAN ORGANIZATION | DIAGNOSED ANAPLASTIC OLIGODENDROGLIOMAS | PHASE-II | LOW-GRADE OLIGODENDROGLIOMA | VINCRISTINE CHEMOTHERAPY | PCV PROCARBAZINE | RECURRENT OLIGODENDROGLIOMA | ONCOLOGY | INITIAL THERAPY | TEMOZOLOMIDE TREATMENT | COMPARATIVE GENOMIC HYBRIDIZATION | Oligodendroglioma - genetics | Oligodendroglioma - pathology | Humans | Brain Neoplasms - pathology | Brain Neoplasms - genetics | Brain Neoplasms - drug therapy | Oligodendroglioma - drug therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Grade II and III Oligodendroglioma and Astrocytoma
by van den Bent, Martin J and Chang, Susan M
Neurologic Clinics, ISSN 0733-8619, 08/2018, Volume 36, Issue 3, pp. 467 - 484
In the 2016 WHO classification of diffuse glioma, the diagnosis of an (anaplastic) oligodendroglioma requires the presence of both an IDH mutation (mt) and... 
PCV | Temozolomide | IDH | 1p/19q codeletion | Anaplastic | Astrocytoma | Bevacizumab | Oligodendroglioma | GROSS-TOTAL RESECTION | PHASE-III | RANDOMIZED-TRIAL | NEUROSCIENCES | CLINICAL NEUROLOGY | BRAIN-TUMOR GROUP | DIAGNOSED ANAPLASTIC OLIGODENDROGLIOMA | TERM-FOLLOW-UP | QUALITY-OF-LIFE | EUROPEAN-ORGANIZATION | SURGICAL RESECTION | 1q/19q codeletion | GLIOMA EORTC 22033-26033
Journal Article
Details down arrow
7. Oligodendrogliomas: Questions answered, answers questioned
by Lassman, Andrew B
ONCOLOGY (United States), ISSN 0890-9091, 2013, Volume 27, Issue 4, pp. 326 - 326
PHASE-III TRIAL | ADJUVANT PROCARBAZINE | RTOG 9402 | ONCOLOGY | PROGRESSION-FREE SURVIVAL | LOMUSTINE | DIAGNOSED ANAPLASTIC OLIGODENDROGLIOMAS | RADIOTHERAPY | VINCRISTINE CHEMOTHERAPY | RADIATION-THERAPY | BRAIN-TUMORS | Brain Neoplasms - drug therapy | Humans | Oligodendroglioma - drug therapy
Journal Article
Details down arrow
8. NCCN Guidelines (R) Insights Central Nervous System Cancers, Version 1.2017 Featured Updates to the NCCN Guidelines
by Nabors, LB and Portnow, J and Ammirati, M and Baehring, J and Brem, H and Butowski, N and Fenstermaker, RA and Forsyth, P and Hattangadi-Gluth, J and Holdhoff, M and Howard, S and Junck, L and Kaley, T and Kumthekar, P and Loeffler, JS and Moots, PL and Mrugala, MM and Nagpal, S and Pandey, M and Parney, I and Peters, K and Puduvalli, VK and Ragsdale, J and Rockhill, J and Rogers, L and Rusthoven, C and Shonka, N and Shrieve, DC and Sills, AK and Swinnen, LJ and Tsien, C and Weiss, S and Wen, PY and Willmarth, N and Bergman, MA and Engh, A
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, ISSN 1540-1405, 11/2017, Volume 15, Issue 11, pp. 1331 - 1345
For many years, the diagnosis and classification of gliomas have been based on histology. Although studies including large populations of patients demonstrated... 
PHASE-III TRIAL | RANDOMIZED EUROPEAN-ORGANIZATION | MOLECULAR CLASSIFICATION | IDH2 MUTATIONS | ADJUVANT PROCARBAZINE | ONCOLOGY | DIAGNOSED ANAPLASTIC OLIGODENDROGLIOMA | CLINICAL-TRIALS | LOW-GRADE GLIOMAS | DIFFUSE GLIOMAS | 1P/19Q LOSS
Journal Article
Details down arrow
9. Full Text Isocitrate dehydrogenase (IDH)1/2 mutations as prognostic markers in patients with glioblastomas
by Chen, Jun-Rui and Yao, Yu and Xu, Hong-Zhi and Qin, Zhi-Yong
Medicine (United States), ISSN 0025-7974, 03/2016, Volume 95, Issue 9, p. e2583
The purpose of this study was to perform a meta-analysis examining the association of isocitrate dehydrogenase (IDH) 1/2 mutations with overall survival (OS)... 
BRAIN-TUMOR GROUP | SURVIVAL | MEDICINE, GENERAL & INTERNAL | GRADE II ASTROCYTOMAS | CODON 132 MUTATION | MGMT | EUROPEAN ORGANIZATION | DIAGNOSED ANAPLASTIC OLIGODENDROGLIOMA | PROCARBAZINE | DIFFUSE GLIOMAS | CHEMOTHERAPY | Prognosis | Humans | Brain Neoplasms - pathology | Proportional Hazards Models | Brain Neoplasms - genetics | Isocitrate Dehydrogenase - genetics | Glioblastoma - therapy | Disease-Free Survival | Glioblastoma - genetics | Glioblastoma - pathology | Brain Neoplasms - therapy | Biomarkers, Tumor - genetics | Mutation | Research | Gene mutations | Glioblastoma multiforme | Risk factors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Oligodendrogliomas in pediatric and adult patients: An outcome-based study from the surveillance, epidemiology, and end result database
by Lau, Christine S. M and Mahendraraj, Krishnaraj and Chamberlain, Ronald S
Cancer Management and Research, ISSN 1179-1322, 05/2017, Volume 9, pp. 159 - 166
Introduction: Oligodendrogliomas (OGs) account for < 20% of all intracranial tumors and 25% of gliomas. Despite improvements in imaging techniques allowing for... 
SEER database | Brain cancer | Oligodendroglioma | oligodendroglioma | BEVACIZUMAB | NEWLY-DIAGNOSED GLIOBLASTOMA | RANDOMIZED-TRIAL | brain cancer | CHEMOTHERAPY | RADIATION-THERAPY | TEMOZOLOMIDE | PHASE-III TRIAL | ADJUVANT PROCARBAZINE | ONCOLOGY | ANAPLASTIC OLIGODENDROGLIOMA | RADIOTHERAPY | Development and progression | Care and treatment | Gliomas | Sentinel health events | Methods | Pediatrics | Nuclear magnetic resonance--NMR | Medical imaging | Mortality | Headaches | Clinical trials | Histology | Radiation therapy | Multivariate analysis | Epidemiology | Cancer therapies | Variance analysis | Clinical outcomes | Data bases | Exports | Chemotherapy | Surveillance | Surgery | Population | Standard deviation | Adults | Age | Tumors | SEER Database | Brain Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text The impact of molecular and clinical factors on patient outcome in oligodendroglioma from 20 years’ experience at a single centre
by Parkinson, Jonathon F and Afaghi, Vahid and Payne, Cathy A and Buckland, Michael E and Brewer, Janice M and Biggs, Michael T and Little, Nicholas S and Wheeler, Helen R and Cook, Raymond J and McDonald, Kerrie L
Journal of Clinical Neuroscience, ISSN 0967-5868, 2010, Volume 18, Issue 3, pp. 329 - 333
Abstract The increased chemosensitivity of oligodendroglial tumours has been associated with loss of heterozygosity (LOH) of the p arm of chromosome 1 and the... 
Neurology | Chemotherapy | Prognosis | Glioma | Chemosensitivity | Survival | Anaplastic oligodendroglioma | Oligodendroglioma | PROGNOSTIC-FACTORS | P53 PROTEIN | OLIGOASTROCYTOMAS | DIAGNOSED ANAPLASTIC OLIGODENDROGLIOMAS | TUMORS | NEUROSCIENCES | CLINICAL NEUROLOGY | TEMOZOLOMIDE | PHASE-III TRIAL | GENE | Immunohistochemistry | Oligodendroglioma - mortality | Oligodendroglioma - genetics | Humans | Middle Aged | Brain Neoplasms - pathology | Kaplan-Meier Estimate | Proportional Hazards Models | Tumor Suppressor Protein p53 - metabolism | Brain Neoplasms - genetics | Male | Loss of Heterozygosity | Young Adult | Chromosomes, Human, Pair 19 - genetics | Drug Resistance, Neoplasm - genetics | Oligodendroglioma - pathology | Adult | Female | Aged | Brain Neoplasms - mortality | Chemotherapy, Adjuvant | Chromosomes, Human, Pair 1 - genetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Chromosomal Aberrations in Canine Gliomas Define Candidate Genes and Common Pathways in Dogs and Humans
by Dickinson, Peter J and York, Dan and Higgins, Robert J and LeCouteur, Richard A and Joshi, Nikhil and Bannasch, Danika
J Neuropathol Exp Neurol, ISSN 0022-3069, 07/2016, Volume 75, Issue 7, pp. 700 - 710
Spontaneous gliomas in dogs occur at a frequency similar to that in humans and may provide a translational model for therapeutic development and comparative... 
Brain tumor | Copy number alteration | Glioma | Dog | Single nucleotide polymorphism (SNP) | Astrocytoma | Cancer genomics | Oligodendroglioma | UNITED-STATES | CLINICALLY RELEVANT SUBTYPES | REPORT PRIMARY BRAIN | PATHOLOGY | NEUROSCIENCES | CLINICAL NEUROLOGY | PROGNOSTIC-FACTOR | SHORT ARM | DIAGNOSED ANAPLASTIC OLIGODENDROGLIOMA | TUMOR-SUPPRESSOR | COMPARATIVE GENOMIC HYBRIDIZATION | COPY-NUMBER ALTERATION | ENDOTHELIAL GROWTH-FACTOR | Species Specificity | Humans | Brain Neoplasms - pathology | Brain Neoplasms - genetics | Genetic Association Studies - methods | Male | Signal Transduction - genetics | Glioma - genetics | Animals | Glioma - pathology | Chromosome Aberrations | Dogs | Cell Line, Tumor | Female | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Temozolomide during and after radiation therapy for WHO grade III gliomas: preliminary report of a prospective multicenter study
by Kim, Young-Hoon and Kim, Young-Hoon and Park, Chul-Kee and Park, Chul-Kee and Cho, Won Ho and Cho, Won Ho and Kim, In Ah and Kim, In Ah and Moon, Seyoung and Moon, Seyoung and Choe, Gheeyoung and Choe, Gheeyoung and Park, Sung-Hye and Park, Sung-Hye and Kim, Il Han and Kim, Il Han and Kim, Dong Gyu and Kim, Dong Gyu and Jung, Hee-Won and Jung, Hee-Won and Lee, Min Mi and Lee, Min Mi and Bae, So Hyun and Bae, So Hyun and Cha, Seung Heon and Cha, Seung Heon and Kim, Chae-Yong and Kim, Chae-Yong
Journal of Neuro-Oncology, ISSN 0167-594X, 7/2011, Volume 103, Issue 3, pp. 503 - 512
This prospective study was performed to determine the efficacy, safety, and tolerability of concurrent chemoradiotherapy (CCRT) followed by adjuvant... 
Neurology | Medicine & Public Health | Concurrent | Oncology | Temozolomide | Chemoradiotherapy | Anaplastic astrocytoma | Anaplastic oligodendroglioma | ADJUVANT CHEMOTHERAPY | ASTROCYTOMA | PROMOTER HYPERMETHYLATION | GLIOBLASTOMA-MULTIFORME | DIAGNOSED ANAPLASTIC OLIGODENDROGLIOMAS | VINCRISTINE PCV CHEMOTHERAPY | PHASE-II | CLINICAL NEUROLOGY | MALIGNANT GLIOMA | TRIAL | ONCOLOGY | 1ST RELAPSE | Glioma - mortality | Prospective Studies | Glioma - diagnosis | Dacarbazine - therapeutic use | Brain Neoplasms - diagnosis | Humans | Middle Aged | Kaplan-Meier Estimate | Probability | Male | Combined Modality Therapy | Brain Neoplasms - drug therapy | Glioma - radiotherapy | Antineoplastic Agents, Alkylating - therapeutic use | Young Adult | Time Factors | Adolescent | Dacarbazine - analogs & derivatives | Adult | Female | Retrospective Studies | Brain Neoplasms - mortality | Brain Neoplasms - radiotherapy | Glioma - drug therapy | Care and treatment | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text A Phase II trial of primary temozolomide in patients with grade III oligodendroglial brain tumors
by Gan, Hui K and Rosenthal, Mark A and Dowling, Anthony and Kalnins, Renate and Algar, Elizabeth and Wong, Nicholas and Benson, Angela and Woods, Anne-Marie and Cher, Lawrence
Neuro-Oncology, ISSN 1522-8517, 05/2010, Volume 12, Issue 5, pp. 500 - 507
Glial tumors with oligodendroglial components are considered chemo-responsive. Forty newly diagnosed patients (11 anaplastic oligodendrogliomas [OD] and 29... 
19q | Oligodendroglial | Temozolomide | MGMT methylation | temozolomide | HYPERMETHYLATION | PROMOTER METHYLATION | oligodendroglial | OLIGOASTROCYTOMAS | DIAGNOSED ANAPLASTIC OLIGODENDROGLIOMAS | CHEMOTHERAPY | CLINICAL NEUROLOGY | 1P/19Q LOSS | GLIOBLASTOMA | ONCOLOGY | MGMT GENE | RADIOTHERAPY | Oligodendroglioma - genetics | Dacarbazine - therapeutic use | Humans | Middle Aged | Brain Neoplasms - pathology | DNA Repair Enzymes - genetics | Male | Antineoplastic Agents - therapeutic use | Loss of Heterozygosity | Young Adult | Chromosomes, Human, Pair 19 - genetics | DNA Methylation | Gene Deletion | Tumor Suppressor Proteins - genetics | Dacarbazine - analogs & derivatives | Adult | Female | Chromosomes, Human, Pair 1 - genetics | Oligodendroglioma - drug therapy | Kaplan-Meier Estimate | Brain Neoplasms - genetics | Brain Neoplasms - drug therapy | Disease-Free Survival | DNA Modification Methylases - genetics | Oligodendroglioma - pathology | Adolescent | Aged | Index Medicus | Clinical Investigations
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text The level of patient-reported outcome reporting in randomised controlled trials of brain tumour patients: A systematic review
by Dirven, Linda and Taphoorn, Martin J.B and Reijneveld, Jaap C and Blazeby, Jane and Jacobs, Marc and Pusic, Andrea and La Sala, Edoardo and Stupp, Roger and Fayers, Peter and Efficace, Fabio and Patient Reported Outcome and EORTC Quality of Life Group (Patient Reported Outcome Measurements Over Time In ONcology-PROMOTION Registry)
European Journal of Cancer, ISSN 0959-8049, 2014, Volume 50, Issue 14, pp. 2432 - 2448
Abstract Background To determine the net clinical benefit of a new treatment strategy, information on both survival and patient-reported outcomes (PROs) is... 
Hematology, Oncology and Palliative Medicine | Patient-reported outcome | Clinical trial | Brain tumour | Clinical decision-making | Quality of life | NEWLY-DIAGNOSED GLIOBLASTOMA | PROGRESSION-FREE SURVIVAL | RECURRENT GLIOBLASTOMA | ADJUVANT TEMOZOLOMIDE | RADIATION-THERAPY | PHASE-III TRIAL | ONCOLOGY | ANAPLASTIC OLIGODENDROGLIOMA | CLINICAL-TRIALS | TERM-FOLLOW-UP | QUALITY-OF-LIFE | Randomized Controlled Trials as Topic - methods | Humans | Middle Aged | Self Report | Brain Neoplasms - therapy | Aged, 80 and over | Quality of Life | Female | Male | Survival Rate | Aged | Patient Outcome Assessment | Brain tumors | Patient outcomes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Decision making and management of gliomas: Practical considerations
by Hottinger, A.F and Homicsko, K and Negretti, L and Lhermitte, B and Stupp, R
Annals of Oncology, ISSN 0923-7534, 09/2012, Volume 23, Issue 10, pp. x33 - x40
Over the last decade, diagnostic options and introduction of novel treatments have expanded the armamentarium in the management of malignant glioma. Combined... 
Chemotherapy | MGMT | IDH1 | Anaplastic astrocytoma | Glioblastoma | Oligodendroglioma | oligodendroglioma | CLINICAL-TRIAL | NEWLY-DIAGNOSED GLIOBLASTOMA | RECURRENT GLIOBLASTOMA | chemotherapy | RADIATION-THERAPY | PHASE-II TRIAL | glioblastoma | STEREOTACTIC RADIOSURGERY | ONCOLOGY | CODON 132 MUTATION | anaplastic astrocytoma | ANAPLASTIC OLIGODENDROGLIOMA | MALIGNANT GLIOMAS | HIGH-GRADE GLIOMAS | Meta-Analysis as Topic | Biomarkers, Tumor - analysis | Dacarbazine - therapeutic use | Humans | Brain Neoplasms - pathology | Brain Neoplasms - drug therapy | DNA Repair Enzymes - analysis | Astrocytoma - pathology | Oligodendroglioma - pathology | Glioblastoma - pathology | Astrocytoma - drug therapy | Dacarbazine - analogs & derivatives | Isocitrate Dehydrogenase - metabolism | Aged | Glioblastoma - drug therapy | DNA Modification Methylases - analysis | Oligodendroglioma - drug therapy | Tumor Suppressor Proteins - analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17.